KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Deffered Revenue (2018 - 2021)

Castle Biosciences' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $172000.0 for Q1 2021.

  • For Q1 2021, Non-Current Deffered Revenue rose 218.52% year-over-year to $172000.0; the TTM value through Mar 2021 reached $172000.0, up 218.52%, while the annual FY2020 figure was $1.7 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q1 2021 was $172000.0 at Castle Biosciences, down from $1.7 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $1.7 million in Q4 2020 and bottomed at $54000.0 in Q1 2020.
  • The 3-year median for Non-Current Deffered Revenue is $172000.0 (2021), against an average of $593528.0.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 1935.5% in 2020 before it surged 218.52% in 2021.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $56006.0 in 2019, then soared by 2997.88% to $1.7 million in 2020, then tumbled by 90.09% to $172000.0 in 2021.
  • Per Business Quant, the three most recent readings for CSTL's Non-Current Deffered Revenue are $172000.0 (Q1 2021), $1.7 million (Q4 2020), and $1.1 million (Q3 2020).